US53635D2027
© Globe Newswire
27.01.2026
LQDA
LISTED
NASDAQ
Liquidia to Present Clinical Data Across Its Portfolio at the Pulmonary Vascular Research Institute 2026 Annual Congress
News Preview
MORRISVILLE, N.C., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company revolutionizing care for patients with challenging respiratory and vascular diseases, announced today the company will present three posters at the Pulmonary Vascular Research Institute (PVRI) 2026 Annual Congress to be held Janua...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.01.2026
LQDA
LISTED
NASDAQ
Liquidia Corporation Announces Preliminary Full-Year 2025 YUTREPIA Net Sales and Corporate Update
News Preview
MORRISVILLE, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced preliminary, unaudited full-year 2025 net product sales of YUTREPIA™ (treprostinil) inhalatio...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.01.2026
LQDA
LISTED
NASDAQ
Liquidia Corporation to Present at 44th Annual J.P. Morgan Healthcare Conference
News Preview
MORRISVILLE, N.C., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Dr. Roger Jeffs, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 beginning at approximately 5:15 p.m. Pacific Time (8:15 p.m. Eastern Time) at the Westin St. Franci...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Globe Newswire
03.11.2025
LQDA
LISTED
NASDAQ
Liquidia Corporation to Present at Upcoming Healthcare Investment Conferences
News Preview
MORRISVILLE, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company revolutionizing care for patients with challenging respiratory and vascular diseases, announced today that members of the company’s executive leadership team will be providing updates on the company's business during fireside chat...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
23.01.2026
© Globe Newswire
03.11.2025
LQDA
LISTED
NASDAQ
Liquidia Corporation Reports Third Quarter 2025 Financial Results and Provides Corporate Update
News Preview
MORRISVILLE, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced its financial results for the third quarter ended September 30, 2025. The company will also ho...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.10.2025
LQDA
LISTED
NASDAQ
Liquidia Corporation to Report Third Quarter 2025 Financial Results on November 3, 2025
News Preview
MORRISVILLE, N.C., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its third quarter 2025 financial results on Monday, November 3, 2025. The company will host a webcast at 8:30 a.m....
Themefolio
Profiler
Peergroup
© Globe Newswire
07.10.2025
LQDA
LISTED
NASDAQ
Liquidia Corporation to Host R&D Day in New York City on October 28, 2025
News Preview
MORRISVILLE, N.C., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that it will host a Research & Development Day (R&D Day) on Tuesday, October 28, 2025, in New York City which will be webcast...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.09.2025
LQDA
LISTED
NASDAQ
Liquidia Announces Poster Presentations at the Pulmonary Hypertension Professional Association (PHPN) Symposium
News Preview
MORRISVILLE, N.C., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that the company will present four posters at the Pulmonary Hypertension Professional Association (PHPN) Symposium taking place Septe...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.08.2025
LQDA
LISTED
NASDAQ
Liquidia Corporation to Present at the 2025 Wells Fargo Healthcare Conference
News Preview
MORRISVILLE, N.C., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that members of the company’s executive leadership team will be providing an update on the company's business during a fireside chat at the 2025 Wells Fargo Healthcare Conference on Wednesday, September 3, 2025, beginning at 3:45 p.m. ET in Bo...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.08.2025
LQDA
LISTED
NASDAQ
Liquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate Update
News Preview
MORRISVILLE, N.C., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases, today announced its financial results for the second quarter ended June 30, 2025. The company will also host a webcast at 8:30 a.m. Eastern Time on A...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.06.2025
LQDA
LISTED
NASDAQ
Liquidia Receives $50 Million from Healthcare Royalty (HCRx) Following First Commercial Sale of YUTREPIA™
News Preview
MORRISVILLE, N.C., June 23, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced the receipt of an additional $50.0 million under its sixth amendment to its financing agreement (HCR Agreement) with Healthcare Royalt...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.05.2025
LQDA
LISTED
NASDAQ
Liquidia Corporation to Present at the 2025 Jefferies Global Healthcare Conference
News Preview
MORRISVILLE, N.C., May 28, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that the company’s Chief Executive Officer Dr. Roger Jeffs, Chief Financial Officer and Chief Operating Officer Michael Kaseta, and Chief Business Officer Jason Adair will be providing an update on the company's business during a fireside chat...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
23.05.2025
LQDA
LISTED
NASDAQ
U.S. FDA Approves Liquidia’s YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
News Preview
MORRISVILLE, N.C., May 23, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that the U.S. Food and Drug Administration (FDA) has approved YUTREPIA™ (treprostinil) inhalation powder, a prostacyclin analog for adu...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.05.2025
LQDA
LISTED
NASDAQ
Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics
News Preview
MORRISVILLE, N.C., May 12, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that United Therapeutics Corporation (UTHR) filed a complaint on May 9, 2025, in the U.S. District Court for the Middle District of Nor...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.05.2025
LQDA
LISTED
NASDAQ
District Court Dismisses Dispute Filed by United Therapeutics Against Liquidia
News Preview
MORRISVILLE, N.C., May 02, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that Judge Kelly of the U.S. District Court for the District of Columbia (District Court) dismissed, without prejudice, the cross-claim...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.05.2025
LQDA
LISTED
NASDAQ
Liquidia Corporation to Report First Quarter 2025 Financial Results on May 8, 2025
News Preview
Liquidia will report its first quarter 2025 financial results on Thursday, May 8, 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
01.04.2025
LQDA
LISTED
NASDAQ
UPDATE – Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference
News Preview
Liquidia Corporation will provide an overview of the company’s business at a fireside chat at the 24th Annual Needham Virtual Healthcare Conference....
Themefolio
Profiler
Peergroup
© Globe Newswire
01.04.2025
LQDA
LISTED
NASDAQ
Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference
News Preview
Liquidia Corporation will provide an overview of the company’s business at a fireside chat at the 24th Annual Needham Virtual Healthcare Conference....
Themefolio
Profiler
Peergroup
© Globe Newswire
19.03.2025
LQDA
LISTED
NASDAQ
Liquidia Corporation Reports Full Year 2024 Financial Results and Provides Corporate Update
News Preview
Liquidia Corporation (NASDAQ: LQDA) today reported financial results for the full year ended December 31, 2024....
Themefolio
Profiler
Peergroup
© Globe Newswire
12.03.2025
LQDA
LISTED
NASDAQ
Liquidia Corporation to Report Full Year 2024 Financial Results on March 19, 2025
News Preview
Liquidia Corporation to Report Full Year 2024 Financial Results on March 19, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.10.2024
LQDA
LISTED
NASDAQ
United States Supreme Court Declines to Review Rulings that Invalidate United Therapeutics’ Patent
News Preview
MORRISVILLE, N.C., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases, today announced that the United States Supreme Court has rejected United Therapeutics’ (UTHR) petition for a writ of certiorari, which requested perm...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.10.2024
LQDA
LISTED
NASDAQ
Liquidia and Pharmosa Biopharm Expand Collaboration to Develop Sustained Release Inhaled Treprostinil (L606)
News Preview
Liquidia and Pharmosa announced they have amended the current exclusive licensing agreement for the development and commercialization of L606....
Themefolio
Profiler
Peergroup
© Globe Newswire
16.09.2024
LQDA
LISTED
NASDAQ
Court Finds United Therapeutics’ Interference with Launch of Generic Treprostinil Injection Caused Losses of More Than $137 Million
News Preview
MORRISVILLE, N.C., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases, announced today that the United States District Court for the District of New Jersey (District Court) has found that the interference by...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.09.2024
LQDA
LISTED
NASDAQ
Liquidia Corporation Announces Raise of $67.5 Million from New Common Stock Financings and $32.5 Million Advance from HealthCare Royalty Under Current Financing Agreement
News Preview
Liquidia Corporation announces raise of $67.5M....
Themefolio
Profiler
Peergroup
© BusinessWire
06.09.2024
LQDA
LISTED
NASDAQ
Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Against Liquidia Technologies, Inc. (LQDA) and Encourages Shareholders to Seek Compensation for Alleged Wrongdoings
News Preview
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Liquidia Technologies, Inc. (“Liquidia” or “the Company”) (NASDAQ: LQDA). Investors who purchased Liquidia securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bga...
Themefolio
Profiler
Peergroup
© BusinessWire
29.08.2024
LQDA
LISTED
NASDAQ
Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Against Liquidia Technologies, Inc. (LQDA) and Encourages Shareholders to Seek Compensation for Alleged Wrongdoings
News Preview
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Liquidia Technologies, Inc. (“Liquidia” or “the Company”) (NASDAQ: LQDA). Investors who purchased Liquidia securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bga...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.08.2024
LQDA
LISTED
NASDAQ
Liquidia to Present at Upcoming Investor Conferences
News Preview
Liquidia Corporation (LQDA) announced today that the company will present at two investor conferences this September....
Themefolio
Profiler
Peergroup
© BusinessWire
27.08.2024
LQDA
LISTED
NASDAQ
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Liquidia Corporation (LQDA)
News Preview
The law firm of Kirby McInerney LLP is investigating potential claims against Liquidia Corporation (“Liquidia” or the “Company”) (NASDAQ: LQDA). The investigation concerns whether Liquidia and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.
[Click here to learn more about...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.08.2024
LQDA
LISTED
NASDAQ
Liquidia Files Litigation to Challenge Regulatory Exclusivity Blocking Access to YUTREPIA™ (treprostinil) inhalation powder for Patients Suffering with PAH and PH-ILD
News Preview
Liquidia has filed litigation that challenges the recent decision by the FDA to grant 3-year new clinical investigation exclusivity to Tyvaso DPI....
Themefolio
Profiler
Peergroup
© BusinessWire
19.08.2024
LQDA
LISTED
NASDAQ
LQDA Investors Have Opportunity to Join Liquidia Corporation Securities Fraud Investigation with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Liquidia Corporation (“Liquidia” or “the Company”) (NASDAQ: LQDA) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed t...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.08.2024
LQDA
LISTED
NASDAQ
U.S. FDA Grants Tentative Approval of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
News Preview
The FDA has granted tentative approval of YUTREPIA™ (treprostinil) inhalation powder to treat adults with PAH and PH-ILD....
Themefolio
Profiler
Peergroup
© Globe Newswire
16.08.2024
LQDA
LISTED
NASDAQ
Liquidia Announces Poster Presentations at the PHA 2024 International PH Conference and Scientific Sessions
News Preview
Liquidia Corporation (NASDAQ: LQDA) will present nine encore thematic posters at the 2024 Pulmonary Hypertension Association (PHA) International Conference...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.05.2024
LQDA
LISTED
NASDAQ
Liquidia Corporation Reports First Quarter 2024 Financial Results and Provides Corporate Update
News Preview
Liquidia Corporation (NASDAQ: LQDA) today reported financial results for the first quarter ended March 31, 2024....
Themefolio
Profiler
Peergroup
© Globe Newswire
10.05.2024
LQDA
LISTED
NASDAQ
Liquidia Announces Poster Presentation at the American Thoracic Society (ATS) 2024 International Conference on Its Open-Label Safety Study of L606 (Liposomal Treprostinil) in Patients with PAH and PH-ILD
News Preview
Liquidia Corporation (NASDAQ: LQDA) announced today the company will present data at the American Thoracic Society (ATS) 2024 International Conference....
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
